Abstract
Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Graphical Abstract
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Berberine in the Treatment of Diabetes Mellitus: A Review
Volume: 21 Issue: 8
Author(s): Aleksandra Baska*, Kamil Leis and Przemysław Gałązka
Affiliation:
- Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, ul. Jagiellonska 13/15, 85-090Bydgoszcz,Poland
Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.
Abstract: Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.
Export Options
About this article
Cite this article as:
Baska Aleksandra*, Leis Kamil and Gałązka Przemysław , Berberine in the Treatment of Diabetes Mellitus: A Review, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (8) . https://dx.doi.org/10.2174/1568026620666201022144405
DOI https://dx.doi.org/10.2174/1568026620666201022144405 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Nanoemulsions: A Better Approach for Antidiabetic Drug Delivery
Current Diabetes Reviews Inhibition of 2C Coxsackie B Virus Protein to Decrease Pathogenicity of Diabetes Mellitus Type 1
Current Computer-Aided Drug Design Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Tombstoning ST-Elevation Myocardial Infarction
Current Cardiology Reviews The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Current Pharmaceutical Design Can Nutrition Play a Role as a Stimulant for COVID 19 in Children?
Reviews on Recent Clinical Trials Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevention of Contrast Induced Nephropathy
Current Drug Therapy